High dose chemotherapy with autologous stem cell support for the treatment of metastatic breast cancer. (Q40657351)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8004629%20AND%20SRC:MED&resulttype=core&format=json

22 October 2019

review article

1 reference

title

High dose chemotherapy with autologous stem cell support for the treatment of metastatic breast cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8004629%20AND%20SRC:MED&resulttype=core&format=json

22 October 2019

main subject

metastatic breast cancer

1 reference

L J Ayash

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8004629%20AND%20SRC:MED&resulttype=core&format=json

22 October 2019

language of work or name

English

0 references

publication date

1 July 1994

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8004629%20AND%20SRC:MED&resulttype=core&format=json

22 October 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8004629%20AND%20SRC:MED&resulttype=core&format=json

22 October 2019

volume

74

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8004629%20AND%20SRC:MED&resulttype=core&format=json

22 October 2019

issue

1 Suppl

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8004629%20AND%20SRC:MED&resulttype=core&format=json

22 October 2019

page(s)

532-535

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8004629%20AND%20SRC:MED&resulttype=core&format=json

Pathologic findings from the National Surgical Adjuvant Project for Breast Cancers (protocol no. 4). X. Discriminants for tenth year treatment failure

22 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.2820741343

7 January 2021

Diverse prognosis in metastatic breast cancer: who should be offered alternative initial therapies?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.2820741343

7 January 2021

Alkylating agent resistance: in vitro studies with human cell lines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.2820741343

7 January 2021

Increasing the therapeutic response rates to anticancer drugs by applying the basic principles of pharmacology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.2820741343

7 January 2021

High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.2820741343

7 January 2021

High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.2820741343

7 January 2021

Cyclophosphamide and thiotepa with autologous bone marrow transplantation in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.2820741343

7 January 2021

A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.2820741343

7 January 2021

Cisplatin as first-line therapy for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.2820741343

7 January 2021

A phase I-II study of bialkylator chemotherapy, high-dose thiotepa, and cyclophosphamide with autologous bone marrow reinfusion in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.2820741343

7 January 2021

A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.2820741343

7 January 2021

High-dose consolidation therapy with autologous stem-cell rescue in stage IV breast cancer: follow-up report

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.2820741343

7 January 2021

Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.2820741343

7 January 2021

High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.2820741343

7 January 2021

Identifiers

DOI

10.1002/CNCR.2820741343

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8004629%20AND%20SRC:MED&resulttype=core&format=json

22 October 2019

1 reference